Looks like NSB are looking to out-licence their product post Phase 1 clinical trials. This has it's own pros and cons. For those not familiar with in/out licencing process the below link will help explain.
https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/what-is-in-licensing/
Ann: Westar Capital Investor Presentation, page-3
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.205M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 214285 | 3.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 75583 | 1 |
View Market Depth
| Last trade - 16.12pm 15/11/2024 (20 minute delay) ? |
| NSB (ASX) Chart |
Day chart unavailable